Dominant GDAP1 mutations cause predominantly mild CMT phenotypes
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Ganglioside-induced differentiation associated-protein 1 (GDAP1) mutations are commonly associated with autosomal recessive Charcot-Marie-Tooth (ARCMT) neuropathy; however, in rare instances, they also lead to autosomal dominant Charcot-Marie-Tooth (ADCMT). We aimed to investigate the frequency of disease-causing heterozygous GDAP1 mutations in ADCMT and their associated phenotype.
Methods: We performed mutation analysis in a large cohort of ADCMT patients by means of bidirectional sequencing of coding regions and exon-intron boundaries of GDAP1. Intragenic GDAP1 deletions were excluded using an allele quantification assay. We confirmed the pathogenic character of one sequence variant by in vitro experiments assaying mitochondrial morphology and function.
Results: In 8 Charcot-Marie-Tooth disease (CMT) families we identified 4 pathogenic heterozygous GDAP1 mutations, 3 of which are novel. Three of the mutations displayed reduced disease penetrance. Disease onset in the affected individuals was variable, ranging from early childhood to adulthood. Disease progression was slow in most patients and overall severity milder than typically seen in autosomal recessive GDAP1 mutations. Electrophysiologic changes are heterogeneous but compatible with axonal neuropathy in the majority of patients.
Conclusions: With this study, we broaden the phenotypic and genetic spectrum of autosomal dominant GDAP1-associated neuropathies. We show that patients with dominant GDAP1 mutations may display clear axonal CMT, but may also have only minimal clinical and electrophysiologic abnormalities. We demonstrate that cell-based functional assays can be reliably used to test the pathogenicity of unknown variants. We discuss the implications of phenotypic variability and the reduced penetrance of autosomal dominant GDAP1 mutations for CMT diagnostic testing and counseling.
GLOSSARY
- ADCMT=
- autosomal dominant Charcot-Marie-Tooth;
- ARCMT=
- autosomal recessive Charcot-Marie-Tooth;
- CMT=
- Charcot-Marie-Tooth;
- DQ=
- dosage quotient;
- GDAP1=
- ganglioside-induced differentiation-associated protein 1;
- MAQ=
- Multiplex Amplicon Quantification;
- NCV=
- nerve conduction velocity;
- PEG=
- polyethylene glycol;
- STR=
- short tandem repeat;
- VFP=
- vocal fold paresis
Footnotes
-
Study funding: This study was supported by the University of Antwerp, the Fund for Scientific Research (FWO-Flanders, grant G017209N), the “Association Belge contre les Maladies Neuromusculaires” (ABMM), the Medical Foundation Queen Elisabeth (GSKE), the Interuniversity Attraction Poles P6/43 program of the Belgian Federal Science Policy Office (BELSPO), the “Methusalem excellence grant” of the Flemish Government, and the Austrian Science Fond (FWF, P19455-B05). M.Z. and J.B. are supported by PhD fellowships of the FWO-Flanders. This study was also supported by the Polish Ministry of Science and Higher Education (grant No. NN 402 27 63 36) to A.K. Work in the laboratory of U.S. is supported by the Swiss National Science Foundation and the NCCR Neural Plasticity and Repair.
-
Editorial, page 520
-
Supplemental data at www.neurology.org
- Received October 21, 2010.
- Accepted February 25, 2011.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Early-onset parkinsonism associated with PINK1 mutationsFrequency, genotypes, and phenotypesV. Bonifati, C. F. Rohé, G. J. Breedveld et al.Neurology, July 11, 2005 -
Articles
Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutationsG. A. Nicholson, C. Magdelaine, D. Zhu et al.Neurology, May 05, 2008 -
Articles
Novel missense mutation in the early growth response 2 gene associated with Dejerine–Sottas syndrome phenotypeV. Timmerman, P. De Jonghe, C. Ceuterick et al.Neurology, June 01, 1999 -
Article
New immunohistochemical method for improved myotonia and chloride channel mutation diagnosticsOlayinka Raheem, Sini Penttilä, Tiina Suominen et al.Neurology, November 14, 2012